QUOIN PHARMACEUTICALS LT-ADR (QNRX)
US74907L3006 - ADR
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty...
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty...
TSLA Stock Alert: Tesla Plunges on Major China Slowdown
Tesla stock is falling on Tuesday as TSLA investors digest the latest delivery data from the EV company and a decrease in China.
Why Is GitLab (GTLB) Stock Down 22% Today?
GitLab stock is falling hard on Tuesday as investors in GTLB react to a lackluster guidance in the company's Q4 earnings report.
Why Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today?
Quoin Pharmaceuticals stock is falling on Tuesday after the company announced the pricing of QNRX shares in a public offering.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start off trading this morning with a breakdown of the biggest pre-market stock movers worth watching on Tuesday!
Quoin Pharmaceuticals files to sell 2.09M shares, warrants (NASDAQ:QNRX)
Quoin Pharmaceuticals files a prospectus for the sale of 2.09M ordinary shares and warrants, emphasizing it's not an offer to sell these securities.
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
Positive initial data and clean safety profile catalyze optimization planSize of both ongoing clinical trials significantly increasedLower dose eliminated...
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits were...
Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET
ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty...
